A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD (opens ClinicalTrials.gov)
- Sponsor
- Regeneron Pharmaceuticals
- Enrolment
- 204
- Started
- 2026-05-22
- Last update
- 2026-09-29
Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions: ALN-PNP, Tirzepatide, Placebo